Prognostic impact and targeting of CRM1 in acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

http://www.wikidata.org/entity/Q36850849

about

Acute Myeloid Leukemia: A Concise Review Structural Basis of Targeting the Exportin CRM1 in Cancer Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus Genomic and molecular characterization of esophageal squamous cell carcinoma Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1 Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.KPT-330 has antitumour activity against non-small cell lung cancer.Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.Atomic basis of CRM1-cargo recognition, release and inhibition Protein mislocalization: mechanisms, functions and clinical applications in cancer.KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents Nucleo-cytoplasmic transport as a therapeutic target of cancer Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential.Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver.Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Biological significance of the importin-β family-dependent nucleocytoplasmic transport pathways.Allosteric control of the exportin CRM1 unraveled by crystal structure analysis.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Targeted therapy of acute myeloid leukemia.Selective inhibitors of nuclear export (SINE) in hematological malignancies.A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.

P2860

Q26766719-68D8FAF4-6319-4DE5-B81C-C3053B98DF92 Q26781513-B5C716F9-FA8F-4009-A86E-82250368993A Q28075654-AFF7AFCE-70EC-4846-9069-EBC4355F2697 Q28548058-85365953-1069-41A7-BA16-F798422D6043 Q28577939-DDC3C38E-4CB4-43D0-AFFF-413CDFBE0720 Q28657686-44FD5EFD-BCF9-4760-B4E3-A7562D028D56 Q33798463-8811F4A1-3BE3-48D7-AD84-CB1546E9DCA5 Q33868512-F800B5E4-52B3-45CB-898A-DAC6D448C2EF Q33918079-F1F8FC7D-77E4-49B7-9A09-1C2631ABC7A6 Q33934010-C7750971-3B97-4EBF-9CD4-34CFEDE2EFC2 Q33940712-5A8966D1-8548-466D-9021-A8049D3D5A9E Q34076405-39DB5558-4DBA-44B1-B4B7-81FA4C0AB95D Q34098446-D337A6EE-5933-4C84-8013-A23FF3AFAAED Q34410193-18651FCC-55D1-4A48-AD29-115935BD5876 Q34441666-D65A3E6E-4566-4959-A43C-220BC9FFFFF9 Q34452108-24FCD2CA-0262-4A73-8ED6-36A5766569FC Q34817365-E05913B8-575A-4300-9553-6D3EA99E1112 Q35171271-679524EE-707E-4F4F-A09D-EC45CB0448B6 Q35764599-79560049-B0B9-4FEB-B6D1-41018CBFDF07 Q35843010-52E8383C-7EAF-4C56-9515-74E2FD79C769 Q35920569-131F7E20-65D0-41B2-9543-2F3A9306CF30 Q35955008-05A62077-2B50-49A2-A6D1-0568512216F0 Q36106299-09E36D5A-E186-4A4E-962A-C4CE8B224544 Q36322776-98560AB3-B9A9-415F-8CBB-9252E4F3B6D0 Q36467373-B34C0DBE-20B0-4F7B-BC87-84EE8380B38B Q36642752-232D4B7B-FDF2-43BA-BD6A-6FF5FB0C1756 Q36734163-7B967032-273F-4FF0-9726-3322BE75A9EF Q36748678-E06E860C-4523-41DE-A350-52518A8777AB Q37002035-2A7D0BCA-844B-4136-A011-CEAE06110F79 Q37086082-70FF02F7-4595-4547-AB0F-5B68FEE948AB Q37263168-EC3B06D5-D9CB-4CCB-AD45-DAB30F57ED5A Q37349113-E31C0DCA-F20D-4D9B-A0CA-789C10C4A62D Q37603441-96084AE6-5276-45D6-9D92-7EC5FBE009C1 Q38207085-4F825350-368E-4B0F-A9D0-3C355CE044C8 Q38211443-5F397E6C-3798-4DC2-A042-980ED9888DB9 Q38260357-1BCF8AE4-D650-42F4-9D14-2197BBCCF882 Q38333251-F410EC34-6FCF-467E-9BA6-7AF0DCD1D64F Q38368605-D581FE58-72C7-40E6-82B8-C02C3DFBC088 Q38812797-7DAA9DDE-3F7D-4217-939B-3749E73B7459 Q38829973-6B6C2789-8304-414F-98A0-60B50A94A7B8

P2860

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

http://www.wikidata.org/entity/Q36850849

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

@en

type

label

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

@en

prefLabel

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

@en

P1433

Q36850849-AFE2C10B-4786-4B3D-8135-1E8213C1AE96

P1476

Q36850849-5E45C533-D8FC-41E3-9048-5C73D19889F9

P2093

Q36850849-00635869-B7F1-40F9-91E5-46812497CCEE

Q36850849-006F8432-770E-48E6-8D62-F7E3F6584B40

Q36850849-0D164CC3-F5ED-4319-9A17-C6D74C6A3186

Q36850849-2637435A-443D-4E2D-A51E-17E5BAF50866

Q36850849-26E148E4-72E7-4378-AEF4-76F3A813482B

Q36850849-33CDF7D9-4C0F-41F1-94F0-42A3D9532092

Q36850849-49B6B506-CD41-4371-B1DA-EAF16BA6E0A8

Q36850849-7CF5417C-7639-40E3-AA27-5DEA5C783AFA

Q36850849-909930F7-0BF7-47EA-8A18-E52008F5013C

Q36850849-96A578F1-A6E8-4B6B-8A1F-0AEE970A41AB

P2860

Q36850849-0C20CDB0-540C-4D2B-BA2A-325BD67C7A9A

Q36850849-2601CB7B-EFC5-47FB-A740-88DA9A2AF949

Q36850849-286C73A9-B415-4D51-80C0-46BC5BAD8D54

Q36850849-2A3873DE-3F98-4B14-B4F7-78AFF66AAA16

Q36850849-2AD06E8F-1FB7-4EA3-8265-9D1173131D7E

Q36850849-2D263DAB-2994-4050-A072-98BCE45BB5A5

Q36850849-334A2C05-F8B0-447F-A9E2-FF80E35A8C77

Q36850849-36CFF8DD-E4F0-49C7-857F-A1C2351AFE88

Q36850849-3CC36572-3390-4ABB-8AC5-F1DD66900A06

Q36850849-3D60D069-C30E-4D79-8A53-48CBADE0C87F

P304

Q36850849-8B12C5B4-A3E2-4704-B286-0F0592460E7A

P31

Q36850849-4C753AAA-1910-4E21-8500-31F19DC6BB1A

P356

Q36850849-7D645CCC-F597-4B0B-8E40-48BAC4B574E0

P407

Q36850849-EEF4C36A-D79F-47C4-8227-B451B16F7697

P433

Q36850849-BF201A1B-35AC-4925-B7BD-6ADEF524F6BA

P478

Q36850849-477556A1-721C-4A1F-BAFE-1E696AEAC440

P50

Q36850849-C3D1943C-E0E5-41C0-A3D4-DBB5A27ECE06

Q36850849-F729DC75-4DBB-47F0-B249-8954C461E013

P577

Q36850849-C34ECC25-2953-4030-99BD-CC3A45B6D86C

P5875

Q36850849-E3B9DCBB-9E50-40C5-8B7F-4958028E98D0

P698

Q36850849-7A441F20-CA9E-4C04-991B-DE28FE3E8755

P921

Q36850849-BFF729E0-A031-40C0-8473-902BC589414E

P932

Q36850849-50C88397-90AF-442C-A13E-2D958C20563B

P356

BLOOD-2012-08-447581

P1433

P1476

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

@en

P2093

Archana Dilip

http://www.w3.org/2001/XMLSchema#string

Jared K Burks

http://www.w3.org/2001/XMLSchema#string

Kensuke Kojima

http://www.w3.org/2001/XMLSchema#string

Kevin R Coombes

http://www.w3.org/2001/XMLSchema#string

Michael Kauffman

http://www.w3.org/2001/XMLSchema#string

Min Zhang

http://www.w3.org/2001/XMLSchema#string

Nianxiang Zhang

http://www.w3.org/2001/XMLSchema#string

R Eric Davis

http://www.w3.org/2001/XMLSchema#string

Seshagiri Duvvuri

http://www.w3.org/2001/XMLSchema#string

Sharon Shacham

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

Nucleophosmin regulates the stability and transcriptional activity of p53

Nuclear export of proteins and drug resistance in cancer

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity

Blinded by the Light: The Growing Complexity of p53

Systematic identification of genomic markers of drug sensitivity in cancer cells

P304

4166-4174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-08-447581

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Michael Andreeff

P577

2013-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236129521

http://www.w3.org/2001/XMLSchema#string

P698

23564911

http://www.w3.org/2001/XMLSchema#string

P921

P932

3656451

http://www.w3.org/2001/XMLSchema#string